Cerebellar Cells Self-Assemble into Functional Organoids on Synthetic, Chemically Crosslinked ECM-Mimicking Peptide Hydrogels.
Animals
Astrocytes
/ physiology
Biomimetic Materials
/ chemistry
Calcium Signaling
Cells, Cultured
Cerebellum
/ cytology
Collagen
/ chemistry
Cross-Linking Reagents
/ chemistry
Extracellular Matrix
/ chemistry
Hydrogels
/ chemistry
Neurons
/ physiology
Oligopeptides
/ chemistry
Organoids
/ cytology
Rats
Rats, Wistar
Tissue Scaffolds
/ chemistry
Ca2+ oscillations
RGD
astrocytes
collagen mimetic peptide
collagen-like peptide
hydrogel
microglia
neurons
tissue engineering
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
12 05 2020
12 05 2020
Historique:
received:
31
03
2020
revised:
28
04
2020
accepted:
02
05
2020
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
10
4
2021
Statut:
epublish
Résumé
Hydrogel-supported neural cell cultures are more in vivo-relevant compared to monolayers formed on glass or plastic substrates. However, there is a lack of synthetic microenvironment available for obtaining standardized and easily reproducible cultures characterized by tissue-mimicking cell composition, cell-cell interactions, and functional networks. Synthetic peptides representing the biological properties of the extracellular matrix (ECM) proteins have been reported to promote the adhesion-driven differentiation and functional maturation of neural cells. Thus, such peptides can serve as building blocks for engineering a standardized, all-synthetic environment. In this study, we have compared the effect of two chemically crosslinked hydrogel compositions on primary cerebellar cells: collagen-like peptide (CLP), and CLP with an integrin-binding motif arginine-glycine-aspartate (CLP-RGD), both conjugated to polyethylene glycol molecular templates (PEG-CLP and PEG-CLP-RGD, respectively) and fabricated as self-supporting membranes. Both compositions promoted a spontaneous organization of primary cerebellar cells into tissue-like clusters with fast-rising Ca
Identifiants
pubmed: 32408703
pii: biom10050754
doi: 10.3390/biom10050754
pmc: PMC7277677
pii:
doi:
Substances chimiques
Cross-Linking Reagents
0
Hydrogels
0
Oligopeptides
0
arginyl-glycyl-aspartic acid
78VO7F77PN
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The CMP PEG-CLP, PEG-CLP-RGD hydrogel matrix technology described in this manuscript is disclosed in Ferentis UAB patents. RV is a majority shareholder and the CEO, and VC, KD, TJ, GS are/were employees of Ferentis UAB.
Références
Front Bioeng Biotechnol. 2020 Sep 04;8:773
pubmed: 33014989
Curr Opin Neurobiol. 2017 Dec;47:138-145
pubmed: 29096242
J Comp Neurol. 2003 Mar 31;458(2):144-57
pubmed: 12596255
Int J Mol Sci. 2015 Mar 11;16(3):5517-27
pubmed: 25768338
Assay Drug Dev Technol. 2014 May;12(4):207-18
pubmed: 24831787
Biotechnology (N Y). 1994 Aug;12(8):797-801
pubmed: 7765020
Methods. 2013 Apr 1;60(2):202-13
pubmed: 23639869
Nat Chem. 2011 Aug 28;3(10):821-8
pubmed: 21941256
Neuron. 2017 May 17;94(4):759-773.e8
pubmed: 28521131
Brain Res. 2012 May 9;1453:8-16
pubmed: 22483961
J Neurosci. 1988 Feb;8(2):709-14
pubmed: 3257519
J Cell Physiol. 2015 Jan;230(1):16-26
pubmed: 24912145
Biomaterials. 2003 Nov;24(24):4337-51
pubmed: 12922147
Tissue Eng Part C Methods. 2015 Dec;21(12):1274-83
pubmed: 26414693
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
J Neurochem. 2001 Mar;76(5):1552-64
pubmed: 11238739
J Cell Sci. 2012 Jul 1;125(Pt 13):3015-24
pubmed: 22797912
Biomaterials. 2015 Jun;54:213-25
pubmed: 25907054
Oncotarget. 2016 Jul 19;7(29):45745-45756
pubmed: 27304190
Prog Neurobiol. 1998 Oct;56(3):307-40
pubmed: 9770242
Tissue Eng Part B Rev. 2016 Jun;22(3):173-82
pubmed: 26669274
BMC Biotechnol. 2012 Sep 14;12:61
pubmed: 22978264
Front Chem. 2019 Mar 27;7:172
pubmed: 31001512
Biotechnol Bioeng. 2009 Jul 1;103(4):655-63
pubmed: 19472329
Sci Rep. 2018 Nov 2;8(1):16279
pubmed: 30389988
Biomaterials. 2010 Nov;31(33):8706-15
pubmed: 20728935
PLoS One. 2015 Sep 28;10(9):e0139472
pubmed: 26414356
Adv Healthc Mater. 2018 Jan;7(1):
pubmed: 28845922
Invest Ophthalmol Vis Sci. 2006 May;47(5):1869-75
pubmed: 16638993
Biomater Sci. 2014 Jun 1;2(6):903-914
pubmed: 25530849
Biomolecules. 2019 Sep 20;9(10):
pubmed: 31547190
J Biomed Mater Res A. 2010 Jun 1;93(3):824-32
pubmed: 19653304
Sci Rep. 2019 Apr 12;9(1):5977
pubmed: 30979929
PLoS One. 2017 Jan 4;12(1):e0169506
pubmed: 28052116
Sci Rep. 2020 Feb 13;10(1):2576
pubmed: 32054865
Science. 2012 Jun 1;336(6085):1124-8
pubmed: 22654050
ACS Appl Mater Interfaces. 2020 Jul 22;12(29):32233-32246
pubmed: 32438798
Acta Biomater. 2013 Mar;9(3):5590-9
pubmed: 23128159
J Biomol NMR. 1995 Jan;5(1):67-81
pubmed: 7881273
Adv Mater. 2011 Jan 18;23(3):349-68
pubmed: 20814918
Brain Pathol. 2014 Nov;24(6):623-30
pubmed: 25345893
FASEB J. 1993 Aug;7(11):996-1003
pubmed: 8370483
Med Eng Phys. 2008 Dec;30(10):1318-37
pubmed: 18614386
J Neurosci. 1982 Sep;2(9):1195-206
pubmed: 6288895
Methods Enzymol. 2004;375:393-414
pubmed: 14870680
Hepatology. 2008 Apr;47(4):1394-400
pubmed: 18307210
Cell Rep. 2018 May 22;23(8):2509-2523
pubmed: 29791859
J Neurosci Res. 1998 Oct 15;54(2):233-47
pubmed: 9788282
eNeuro. 2015 Aug 31;2(4):
pubmed: 26464992